Outcomes of Roux-En-Y Gastric Bypass and Sleeve Gastrectomy in the Super-Obese and Super-Super-Obese: An Analysis of the Metabloic and Bariatric Surgery Accreditation and Quality Improvement Program Database by Nasser, Hassan et al.
Henry Ford Health System
Henry Ford Health System Scholarly Commons
Clinical Research Medical Education Research Forum 2019
5-2019
Outcomes of Roux-En-Y Gastric Bypass and Sleeve
Gastrectomy in the Super-Obese and Super-Super-
Obese: An Analysis of the Metabloic and Bariatric
Surgery Accreditation and Quality Improvement
Program Database
Hassan Nasser
Henry Ford Health System, hnasser2@hfhs.org
Tommy Ivanics
Henry Ford Health System, tivanic1@hfhs.org
Shravan Leonard-Murali
Henry Ford Health System, SMurali1@hfhs.org
Dania Shakaroun
Henry Ford Health System, DShakar1@hfhs.org
Jeffrey A. Genaw
Henry Ford Health System, Jgenaw1@hfhs.org
Follow this and additional works at: https://scholarlycommons.henryford.com/merf2019clinres
This Poster is brought to you for free and open access by the Medical Education Research Forum 2019 at Henry Ford Health System Scholarly
Commons. It has been accepted for inclusion in Clinical Research by an authorized administrator of Henry Ford Health System Scholarly Commons.
For more information, please contact acabrer4@hfhs.org.
Recommended Citation
Nasser, Hassan; Ivanics, Tommy; Leonard-Murali, Shravan; Shakaroun, Dania; and Genaw, Jeffrey A., "Outcomes of Roux-En-Y
Gastric Bypass and Sleeve Gastrectomy in the Super-Obese and Super-Super-Obese: An Analysis of the Metabloic and Bariatric






Prevalence growth by severity of  obesity. 
Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med. 2003;163(18):2146-2148. 
Background
 Super-obese (SO): BMI 50 – 60 kg/m2 
 Super-super-obese (SSO): BMI ≥ 60 kg/m2
 Bariatric surgery constitutes a treatment challenge in this group:
 Associated co-morbidities
 Increased abdominal wall thickness
 Increased visceral fat
 Hepatic hypertrophy 
Aim
 Conflicting evidence regarding outcomes for laparoscopic Roux-en-Y gastric bypass 
in SO and SSO
 Minimal data on the outcomes of  laparoscopic sleeve gastrectomy in SO and SSO
 Most data comes from single center studies with small sample sizes
 Our aim is to evaluate operative outcomes of laparoscopic sleeve gastrectomy 
(LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB) in SO and SSO 
patients using the Metabolic and Bariatric Surgery Accreditation and Quality 
Improvement Program (MBSAQIP) database
Methods
 MBSAQIP database for LSG and LRYGB from 2015 to 2017
 Excluded:
 Revisions or conversions
 Emergent cases
 Age < 18 years
 BMI < 35 kg/m2
 Missing data
 356,621 patients were identified
Methods
 Stratified by BMI groups
 BMI 35-49 kg/m2: morbidly obese (MO)
 BMI 50-59 kg/m2: super-obese (SO)
 BMI > 60 kg/m2: super-super-obese (SSO)
 Univariate analysis was used to compare patient characteristics 
 Multivariate logistic regression models were used to evaluate the effect of  
BMI on postoperative outcomes










198656 (73.0%) 44078 (67.2%) 12725 (67.5%)
Laparoscopic Roux-en-Y 
gastric bypass
73539 (27.0%) 21487 (32.8%) 6136 (32.5%)









Age, yr 45.2 ± 11.9 42.7 ± 11.8 41.3 ± 11.1 < 0.001
Sex
Female 219828 (80.8%) 49384 (75.3%) 13459 (71.4%)
< 0.001
Male 52367 (19.2%) 16181 (24.7%) 5402 (28.6%)
Race Group
White 202754 (74.5%) 45638 (69.6%) 12407 (65.8%)
< 0.001African American 43735 (16.1%) 14209 (21.7%) 4993 (26.5%)
Other 25706 (9.45%) 5718 (8.72%) 1461 (7.75%)
BMI, kg/m2 42.4 ± 3.87 53.9 ± 2.75 66.7 ± 7.44 < 0.001









Coronary artery disease 8957 (3.29%) 1961 (2.99%) 465 (2.47%) < 0.001
Hypertension 128184 (47.1%) 34228 (52.2%) 10909 (57.8%) < 0.001
Diabetes mellitus 69697 (25.6%) 18241 (27.8%) 5481 (29.1%) < 0.001
COPD 4210 (1.55%) 1409 (2.15%) 547 (2.90%) < 0.001
Oxygen Dependent 1390 (0.51%) 709 (1.08%) 485 (2.57%) < 0.001
OSA 96745 (35.5%) 30440 (46.4%) 10460 (55.5%) < 0.001
Smoker 22763 (8.36%) 6305 (9.62%) 1885 (9.99%) < 0.001
Renal Insufficiency 1630 (0.60%) 476 (0.73%) 152 (0.81%) < 0.001
Dialysis 789 (0.29%) 191 (0.29%) 42 (0.22%) 0.241
DVT/PE 5542 (2.04%) 1999 (3.05%) 850 (4.51%) < 0.001
Use of assistive device 3203 (1.18%) 1529 (2.33%) 999 (5.30%) < 0.001
Dependent functional status 2015 (0.74%) 887 (1.35%) 610 (3.23%) < 0.001











83 (0.04%) 34 (0.08%) 13 (0.10%) < 0.001
Operation Length, 
min
70.2 ± 34.7 73.8 ± 37.1 77.9 ± 38.4 < 0.001
Length of stay, 
days
1.57 ± 1.28 1.62 ± 1.19 1.79 ± 2.28 < 0.001










98 (0.13%) 35 (0.16%) 29 (0.47%) < 0.001
Operation Length, 
min
116.1 ± 52.0 118.8 ± 52.6 120.9 ± 52.4 < 0.001
Length of stay, 
days
1.97 ± 1.66 2.06 ± 2.47 2.27 ± 2.47 < 0.001
Table 5. Operative details for laparoscopic Roux-en-Y gastric 
bypass.
Results















Any complication 5060 (2.55%) 1482 (3.36%) 582 (4.57%) < 0.001 4355 (5.92%) 1419 (6.60%) 532 (8.67%) < 0.001
Mortality 82 (0.04%) 35 (0.08%) 23 (0.18%) < 0.001 72 (0.10%) 37 (0.17%) 20 (0.33%) < 0.001
Table 6. Primary outcomes for laparoscopic sleeve gastrectomy and Roux-en-Y 
gastric bypass for each BMI group.
Results
Laparoscopic sleeve gastrectomy Laparoscopic Roux-en-Y gastric bypass
SO SSO SO SSO
Any complication 1.20 (1.13 – 1.28) 1.44 (1.31 – 1.58) 1.08 (1.01 – 1.15) 1.31 (1.19 – 1.45)
Mortality 1.65 (1.10 – 2.48) 3.30 (1.98 – 5.48) 1.85 (1.23 – 2.80) 3.32 (1.93 – 5.73)
Table 7. Adjusted odds ratio (95% confidence interval) for primary outcomes for 
laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass.
* Significant variables (P < 0.050) are in bold
Conclusion 
 LSG and LRYGB are associated with minimal increase in 
operative times, conversion to open, and length of  stay in SO 
and SSO patients compared to MO patients.
 LSG and LRYGB are associated with increased overall 30-day 
perioperative morbidity and mortality in SO and SSO patients 
compared to MO patients. 
Limitations 
 Retrospective design
 Inability to adjust for confounders not included in the database
Future Directions
Future Directions
Sinha, A. et al. Enhanced recovery after bariatric surgery in the severely obese, morbidly obese, super-morbidly obese, and super-super 
morbidly obese using evidence-based clinical pathways: a comparative study. Obesity Surgery. 2017;27:560-568.
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